<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127931">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02127775</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA594-132</org_study_id>
    <nct_id>NCT02127775</nct_id>
  </id_info>
  <brief_title>Lesinurad Tablet Bioequivalence</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Crossover Study to Assess the Bioequivalence of Lesinurad Tablets From Two Manufacturing Sites in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the bioequivalence of lesinurad tablets manufactured at two different
      sites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is intended to evaluate the clinical comparability of lesinurad tablets
      manufactured at the 2 different sites by assessing relevant clinical Pharmacokinetics (PK)
      parameters.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>PK profile of lesinurad from plasma</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK endpoints in terms of maximum observed concentration (Cmax); time of occurrence of maximum observed concentration (tmax); area under the plasma concentration time curve from zero to 24 hours post dose (AUC last) and from zero to infinity (AUC ∞); and apparent terminal half-life (t1/2). Point estimates and 90% confidence intervals for the ratio of geometric means for Cmax, AUC last and AUC∞ between test and reference formulations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Changes in Laboratory, Electrocardiogram and Vital Signs Parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1:  Lesinurad 400 mg (manufactured at Site 2); Day 5: Lesinurad 400 mg (manufactured at Site 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Lesinurad 400 mg (manufactured at Site 1); Day 5: Lesinurad 400 mg (manufactured at Site 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lesinurad 400 mg (manufactured at Site 1)</intervention_name>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lesinurad 400 mg (manufactured at Site 2)</intervention_name>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40
             kg/m2.

          -  Subject has a Screening serum urate level ≤ 7 mg/dL. ˗ Subject is free of any
             clinically significant disease or medical condition, per the Investigator's judgment.

        Exclusion Criteria:

          -  Subject has any gastrointestinal disorder that affects motility and/or absorption.

          -  Subject has a history or suspicion of kidney stones.

          -  Subject has undergone major surgery within 3 months prior to Screening.

          -  Subject has donated blood or experienced significant blood loss (&gt; 450 mL) within 12
             weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to the Screening
             visit.

          -  Subject has inadequate venous access or unsuitable veins for repeated venipuncture.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Hall</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>C. Winnett</last_name>
    <phone>858.652.6649</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 1, 2014</lastchanged_date>
  <firstreceived_date>April 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
